Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Lampert Mark N
Relationship:   10% Owner
City:   San Francisco
State:   CA
   
Insider Summary:
  
   
Companies Owned :   44    
Direct Shares   110,762,579    

Indirect Shares

   88,557,834      
Direct Value   $1,402,314,851    

Indirect Value

   $1,620,379,579      
Total Shares   199,320,413      
Total Value   $3,022,694,430      


Repligen Corp $535,862,873 Dynavax Technologies Corp $69,424,102 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,042,609 Alpine Immune Sciences Inc $13,028,918 Glycomimetics Inc $1,033,943 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,790,900 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $30,268,363 Merus Nv $10,482,925 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $298,760 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $184,138,161 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,613,376 Structure Therapeutics Inc. $201,473,263 Engene Holdings Inc. $34,432,398 Allakos Inc. $16,639,129 Repligen Corp $535,862,873 Dynavax Technologies Corp $69,424,102 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,042,609 Alpine Immune Sciences Inc $13,028,918 Glycomimetics Inc $1,033,943 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,790,900 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $30,268,363 Merus Nv $10,482,925 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $298,760 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $184,138,161 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,613,376 Structure Therapeutics Inc. $201,473,263 Engene Holdings Inc. $34,432,398 Allakos Inc. $16,639,129
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    50   
    13    

     Stock price went up :
    40   
    4    
     Stock price went down :
    10   
    9    
   
     Gain/Loss Ratio :
   4.0   
   4.0   
     Percentage Gain/Loss :
   103.0%
 -82.1%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Arena Pharmaceuticals Inc ARNA Director, 10% Owner 2003-10-17 0 2003-10-17 4,520,212    Premium*  
            Repligen Corp RGEN 10% Owner 2009-05-15 3,216,850 0    Premium*  
            Dynavax Technologies Corp DVAX Indirect Beneficial Ow... 2009-06-19 6,193,051 2009-06-19 18,579,153    Premium*  
            Adolor Corp ADLR 10% Owner 2009-09-22 4,123,551 2009-09-22 12,370,653    Premium*  
            Gyre Therapeutics GYRE 10% Owner 0 2012-11-08 1,052,258    Premium*  
            Arqule Inc ARQL 10% Owner 2018-05-30 771,305 2010-04-05 12,624,219    Premium*  
            Astex Pharmaceuticals Inc ASTX 10% Owner 2010-04-20 5,583,399 2010-04-20 16,750,197    Premium*  
            Capstone Therapeutics Corp CAPS See Explanation of Res... 2011-06-27 0 2017-07-14 890,487    Premium*  
            Ligand Pharmaceuticals Inc LGND See Explanation of Res... 0 2014-03-25 130,175    Premium*  
            Icagen Inc ICGN 10% Owner 2011-09-07 0 2011-09-07 625,400    Premium*  
            Palatin Technologies Inc PTN 10% Owner 0 2014-02-27 2,494,521    Premium*  
            Neurocrine Biosciences Inc NBIX 10% Owner 2011-10-10 0 2011-10-12 3,527,700    Premium*  
            Kent International Inc KNTH See Explanation of Res... 2011-12-23 0 2011-12-23 0    Premium*  
            Chemocentryx, Inc. CCXI 10% Owner 0 2012-11-06 3,750,277    Premium*  
            Rigel Pharmaceuticals Inc RIGL 10% Owner 0 2013-06-07 7,761,738    Premium*  
            Cascadian Therapeutics, Inc CASC 10% Owner 2013-06-05 0 2015-02-05 1,898,293    Premium*  
            Tobira Therapeutics Inc TBRA See Explanation of Res... 0 2014-03-21 1,121,221    Premium*  
            Cti Biopharma Corporation CTIC See Explanation of Res... 2023-06-26 0 2023-06-26 0    Premium*  
            Infinity Pharmaceuticals Inc INFI 10% Owner 2021-02-11 534,847 2016-12-01 0    Premium*  
            XOMA Corporation XOMA Director, 10% Owner 2023-01-06 1,693,924 2023-01-06 361,774    Premium*  
            Alpine Immune Sciences Inc ALPN 10% Owner 2017-06-20 201,811 2017-05-09 0    Premium*  
            Glycomimetics Inc GLYC 10% Owner 2020-11-04 630,453 0    Premium*  
            Xenon Pharmaceuticals Inc. XENE 10% Owner 2018-03-27 59,464 2017-06-06 0    Premium*  
            Concert Pharmaceuticals, Inc. CNCE 10% Owner 2019-06-10 169,589 2017-10-19 0    Premium*  
            Syndax Pharmaceuticals Inc SNDX 10% Owner 2018-06-18 85,038 2018-06-18 0    Premium*  
            Immune Design Corp. IMDZ 10% Owner 2018-12-04 370,391 2018-12-04 0    Premium*  
            Pieris Pharmaceuticals, Inc. PIRS 10% Owner 2023-05-11 20,333,557 2019-01-30 0    Premium*  
            Calithera Biosciences, Inc. CALA 10% Owner 2020-05-21 480,432 0    Premium*  
            Five Prime Therapeutics Inc FPRX 10% Owner 2021-03-04 6,262,085 0    Premium*  
            Cytokinetics Inc CYTK See Explanation of Res... 2020-12-09 463,244 2019-12-10 0    Premium*  
            Merus Nv MRUS 10% Owner 2021-10-08 232,747 0    Premium*  
            Ideaya Biosciences, Inc. IDYA See Explanation of Res... 2021-02-02 233,150 2020-06-19 0    Premium*  
            Kymera Therapeutics, Inc. KYMR See Remarks and Footno... 2023-11-03 294,632 2020-08-21 0    Premium*  
            Eledon Pharmaceuticals Ord Shs ELDN 10% Owner 2023-05-05 145,029 0    Premium*  
            Olema Pharmaceuticals, Inc. OLMA Director, 10% Owner 2023-09-12 524,151 2023-09-14 99,556    Premium*  
            Cytomx Therapeutics, Inc. CTMX 10% Owner 2020-12-18 5,468,599 0    Premium*  
            Rain Therapeutics Inc. RAIN See Remarks; Former 10... 2024-01-25 0 2021-04-23 0    Premium*  
            Repare Therapeutics Inc. RPTX 10% Owner 2023-11-16 548,938 0    Premium*  
            Verastem, Inc. VSTM 10% Owner 2022-01-25 19,630,934 0    Premium*  
            ESSA Pharma Inc EPIX 10% Owner 2022-07-11 8,561,841 0    Premium*  
            Third Harmonic Bio, Inc. THRD 10% Owner 2022-12-20 241,309 2022-12-20 0    Premium*  
            Structure Therapeutics Inc. GPCR 10% Owner 2023-05-10 5,173,941 0    Premium*  
            Engene Holdings Inc. ENGN 10% Owner 2023-10-31 2,221,445 0    Premium*  
            Allakos Inc. ALLK 10% Owner 2024-01-16 16,312,872 0    Premium*  
* Premium Members only  

Records found :    355         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 1 of 15
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
KNTH Kent International Inc See Explanation of Responses   –       –      –    2011-12-23 4 D $2.50 $1,814,015 I/I (725,606) 0 0 -
CTIC Cti Biopharma Corporation 10% Owner   –       –       •   2018-02-09 4 D $0.00 $0 D/D (6,512,706) 0 0 -
GPCR Structure Therapeutics In... 10% Owner   –       –       •   2023-05-10 4 D $0.00 $0 D/D (7,410,518) 0 0 -
CTIC Cti Biopharma Corporation See Explanation of Responses   –       •       •   2023-06-26 4 D $9.10 $66,310,553 D/D (7,286,874) 0 0 -
CTIC Cti Biopharma Corporation See Explanation of Responses   –       •       •   2023-06-26 4 D $9.10 $14,280,503 I/I (1,569,286) 0 0 -
RAIN Rain Therapeutics Inc. See Remarks; Former 10% Owner   –       •      –    2024-01-25 4 D $0.00 $0 D/D (5,288,617) 0 0 -
RAIN Rain Therapeutics Inc. See Remarks; Former 10% Owner   –       •      –    2024-01-25 4 D $0.00 $0 D/D (3,288,186) 0 0 -
CTIC Cti Biopharma Corporation See Explanation of Responses   –       •       •   2022-08-09 4 S $6.12 $7,891,336 I/I (1,289,434) 6,148 0 %
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-04-23 4 A $0.00 $0 D/D 217,033 17,390 0 -
CTIC Cti Biopharma Corporation See Explanation of Responses   –       •       •   2022-08-09 4 S $6.12 $44,128,664 D/D (7,210,566) 19,839 0 %
XENE Xenon Pharmaceuticals Inc... 10% Owner   –       –       •   2018-03-27 4 D $0.00 $0 D/D (2,437,000) 59,464 0 -
XOMA XOMA Corporation 10% Owner   –       –       •   2021-03-31 4 S $38.36 $21,857,413 D/D (569,797) 75,287 0 %
LGND Ligand Pharmaceuticals In... 10% Owner   –       –       •   2014-02-20 4 S $73.05 $10,730,737 I/I (146,900) 79,390 0 -
FPRX Five Prime Therapeutics I... See Explanation of Responses   –       –      –    2020-11-11 4 S $20.19 $149,247,137 D/D (7,393,340) 81,263 0 %
LGND Ligand Pharmaceuticals In... 10% Owner   –       –       •   2014-02-19 4 S $73.03 $5,477,497 I/I (75,000) 84,749 0 -
SNDX Syndax Pharmaceuticals In... 10% Owner   –       –       •   2018-06-18 4 D $0.00 $0 D/D (2,000,000) 85,038 0 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-04-23 4 A $15.93 $18,694,901 D/D 1,105,896 86,479 0 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-04-23 4/A B $15.93 $18,694,901 D/D 1,105,896 86,479 2.44 -
LGND Ligand Pharmaceuticals In... 10% Owner   –       –       •   2014-02-18 4 S $74.66 $15,005,876 I/I (201,000) 87,520 0 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-04-26 4 A $14.90 $408,478 D/D 27,413 88,226 0 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-04-26 4/A B $14.90 $408,478 D/D 27,413 88,226 2.44 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-05-13 4 B $14.26 $827,167 D/D 58,000 91,700 2.44 -
OLMA Olema Pharmaceuticals, In... 10% Owner   –       –       •   2021-03-31 4 A $0.00 $0 I/I 99,556 99,556 0 -
OLMA Olema Pharmaceuticals, In... Director   –       •       •   2023-09-14 4 A $0.00 $0 I/I 99,556 99,556 0 -
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-05-18 4 B $16.65 $3,183,430 D/D 191,197 103,646 2.44 -
  355  Records found
  1  2   3   4   5   6   7   8   9   10   11   12   13   14   15      
  Page 1 of 15  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us